Vanguard Group Inc. Increases Position in Arvinas, Inc. (NASDAQ:ARVN)

Vanguard Group Inc. boosted its stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 0.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,062,561 shares of the company's stock after buying an additional 56,561 shares during the period. Vanguard Group Inc. owned approximately 10.28% of Arvinas worth $135,389,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ARVN. JPMorgan Chase & Co. raised its stake in shares of Arvinas by 18.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company's stock valued at $57,371,000 after acquiring an additional 367,343 shares during the period. Barclays PLC raised its position in Arvinas by 198.9% in the third quarter. Barclays PLC now owns 121,699 shares of the company's stock valued at $2,998,000 after purchasing an additional 80,984 shares during the period. Monaco Asset Management SAM purchased a new stake in Arvinas in the fourth quarter valued at approximately $479,000. Nomura Asset Management Co. Ltd. lifted its stake in Arvinas by 36.3% during the third quarter. Nomura Asset Management Co. Ltd. now owns 90,870 shares of the company's stock worth $2,238,000 after purchasing an additional 24,223 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Arvinas by 228.8% during the fourth quarter. SG Americas Securities LLC now owns 32,424 shares of the company's stock worth $622,000 after buying an additional 22,564 shares during the period. Institutional investors and hedge funds own 95.19% of the company's stock.

Arvinas Trading Up 5.0 %

NASDAQ:ARVN traded up $0.33 during midday trading on Friday, hitting $6.95. 2,851,035 shares of the company were exchanged, compared to its average volume of 1,085,943. Arvinas, Inc. has a fifty-two week low of $5.94 and a fifty-two week high of $38.56. The company has a market capitalization of $477.97 million, a PE ratio of -2.51 and a beta of 2.30. The company has a fifty day simple moving average of $12.58 and a 200 day simple moving average of $19.18.

Remove Ads

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the company posted ($2.53) earnings per share. As a group, equities research analysts expect that Arvinas, Inc. will post -3.81 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ARVN. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a report on Friday, February 7th. HC Wainwright reissued a "buy" rating and set a $81.00 price target on shares of Arvinas in a research report on Monday, April 7th. Wedbush cut shares of Arvinas from an "outperform" rating to a "neutral" rating and dropped their price objective for the company from $57.00 to $12.00 in a report on Wednesday, March 12th. Guggenheim decreased their price target on shares of Arvinas from $57.00 to $32.00 and set a "buy" rating for the company in a research report on Thursday, March 13th. Finally, Stifel Nicolaus cut their price objective on Arvinas from $63.00 to $51.00 and set a "buy" rating on the stock in a research report on Wednesday, February 12th. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Arvinas presently has an average rating of "Moderate Buy" and an average price target of $34.53.

Insider Activity

In other news, CEO John G. Houston sold 31,338 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the sale, the chief executive officer now owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. This trade represents a 2.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Noah Berkowitz sold 8,658 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the transaction, the insider now owns 110,023 shares in the company, valued at approximately $945,097.57. This trade represents a 7.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,230 shares of company stock valued at $769,402. 5.23% of the stock is currently owned by company insiders.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.